ArticleBMJ global health2022

Ultraexpensive gene therapies, industry interests and the right to health: the case of onasemnogene abeparvovec in Brazil.

Adriana Mitsue Ivama-Brummell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.